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OPTIMAL THERAPY OF HEPATITIS C DYNAMICS AND SAMPLING BASED ANALYSIS
GAURAV PACHPUTE ∗ SIDDHARTHA P. CHAKRABARTY †
Abstract
We examine two models for hepatitis C viral (HCV) dynamics, one for monotherapy with interferon
(IFN) and the other for combination therapy with IFN and ribavirin. Optimal therapy for both the models
is determined using the steepest gradient method, by defining an objective functional which minimizes
the infected hepatocyte levels, virion population and the side-effects of the drug(s). The optimal therapy
for both the models shows an initial period of high efficacy, followed by a gradual decline. The period of
high efficacy coincides with a significant decrease in the infected hepatocyte levels as well as viral load,
whereas the efficacy drops after liver regeneration through restored hepatocyte levels. The period of high
efficacy is not altered significantly when the cost coefficients are varied, as long as the side effects are
relatively small. This suggests a higher dependence of the optimal therapy on the model parameters in
case of drugs with minimal side effects.
We use the Latin hypercube sampling technique to randomly generate a large number of patient
scenarios (i.e, model parameter sets) and study the dynamics of each set under the optimal therapy
already determined. Results show an increase in the percentage of responders (as indicated by drop in
viral load below detection levels) in case of combination therapy as compared to monotherapy. Statistical
tests performed to study the correlations between sample parameters and the time required for the viral
load to fall below detection level, show a strong monotonic correlation with the death rate of infected
hepatocytes, identifying it to be an important factor in deciding individual drug regimens.
Keywords: Hepatitis C, Optimal Control, Steepest-Gradient Method, Latin Hypercube Sampling,
Statistical Tests
1 INTRODUCTION
Hepatitis C (HCV) is an infectious disease which spreads through blood contact. It is estimated that
HCV has infected 170 million individuals worldwide [1]. Roe and Hall [2] estimate that about 50 − 80%
of HCV infected cases are chronic in nature. Of these chronic cases, about 10 − 20% develop into liver
cirrhosis of which, about 5% develop hepatocellular carcinoma (HCC). The extend of prevalence of HCV
varies widely across geographical locations [3, 4]. While the dominant mode of HCV transmission in United
States, Europe and Australia is injecting drug use [3], the absence of reliable screening for HCV amongst
blood donors remains a major challenge in combating the spread of the disease in India [5, 6].
Mathematical modelling and quantitative analysis of hepatitis C infections has been explored extensively
over the last decade. Most of the modelling has been restricted to the short term dynamics of the model. One
of the earliest models was proposed by Neumann et al. [7], who examine the dynamics of HCV in presence
of Interferon-α (IFN-α) treatment. They find that the primary role of IFN is in blocking the production
of virions from the infected hepatocytes. However, IFN has little impact when it comes to controlling the
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infection of the hepatocytes. Dixit et al. [8] improved upon [7] by including the effects of ribavirin , which
in turn results in a fraction of the virions being rendered noninfectious. Their model is able to explain
clinically observed biphasic decline patterns amongst patient population. Their study also shows that while
IFN plays a pivotal role in the first phase decline of viral load, ribavirin has very little impact. However,
in case of low IFN efficacy, ribavirin makes a significant contribution to the second phase of decline. The
model could not successfully explain the triphasic decline patterns, as well as some cases of non-responders.
Dahari et al. [9] in a subsequent and improved model, take into account the homeostatic mechanisms for the
liver by incorporating a growth function. This model successfully explains the triphasic decline, as well as
therapeutic failures.
Control theory has found wide ranging applications in biological and ecological problems [10]. In
biomedical problems, techniques from control theory are of great use in developing optimal therapeutic
strategies. The treatment regimen is usually taken to be the control variable, with the aim of minimizing the
detrimental effects of the medical condition. For instance, in cancer modeling, DePillis et al. [11] examine
a mathematical model of tumor-immune interactions and determine the optimal chemotherapy with the goal
of minimizing the tumor density, as well as the therapeutic side effects, for both linear and quadratic con-
trol. Fister and Panetta [12] consider three different cell-kill models and determine the optimal drug dosage
which minimizes the cancer mass and the cost of treatment for all three models. Murray [13] uses linear
control approach for cancer chemotherapy models with toxicity limit. Optimal control theory can be applied
to epidemic models, such as the SEIR model, with the goal of minimizing the number of infectious individ-
uals and the overall cost of the vaccination programme [10]. In case of treatment of diabetes, the control is
taken as the insulin injection levels with the objective of minimizing the difference between current and the
desired glucose levels. Chavez et al. [14] present an optimal insulin delivery for type 1 diabetic patients.
Control theoretic approach has been applied extensively in case of virological models, especially in case
of HIV models. One of the earliest papers in this area by Kirschner et al. [15] uses an existing ODE
model which incorporates the dynamics of the immune system and HIV. Using an objective functional
which maximizes the levels of T-cells and minimizes the cost of treatment, the optimal chemotherapy (like
protease inhibitors) is determined for various stages of initiation of treatment. Joshi [16] considers a model
with combination therapy and numerically solves the optimal system for the optimal treatment regimen.
Adams et al. [17] present the optimal treatment protocols (along with modeling and data analysis) for HIV
dynamics. Stengel [18], in his paper, obtains the optimal therapies for drug resistant strains of HIV which
evolve rapidly, as a result of high viral turnover and mutation rates. He observes that in such cases continued
treatment is imperative for sustained remission.
In the case of HCV, Chakrabarty and Joshi [19] consider a model (motivated by [7, 8, 9]) for HCV
dynamics under combination therapy of interferon and ribavirin. An objective functional is formulated to
minimize the viral load, as well as the drug side-effects and the optimal system is solved numerically to
determine optimal efficacies of the drugs. Chakrabarty [20] extended the results in [19] by considering a
clinically validated functional form for the interferon efficacy and hence determined the optimal efficacy
of ribavirin. Martin et al. [21] in a recent paper examine a three compartment model for HCV, involving
the susceptible, chronically infected and treated injecting drug users (IDUs). They determine an optimal
treatment programme over a 10 year period taking into account several biomedical and economic objectives.
2 MODEL FOR MONOTREATMENT WITH IFN
We first consider a three dimensional model given by Dahari et al. [9] based on an earlier pioneering
model of Neumann et al. [7]. The model describes the dynamics of the the uninfected and infected hepato-
2
cytes as well as the HCV and is expressed as a system of three coupled ordinary-differential equations:
dT
dt
= s+ rT
(
1−
T + I
Tmax
)
− dT − βTV
dI
dt
= βTV + rI
(
1−
T + I
Tmax
)
− δI
dV
dt
= (1− ǫp)pI − cV. (2.1)
The uninfected hepatocytes (T ) are being produced at a rate s and proliferate logistically at a rate r, ac-
companied by a natural death rate of d. The homeostatic liver mechanism is incorporated through Tmax,
which is the maximum hepatocyte count in the liver. HCV (V ) is assumed to infect the hepatocytes at a
rate β, thereby producing infected hepatocytes (I). The infected hepatocytes are also assumed to proliferate
logistically at a rate r and have a natural death rate of δ. In the absence of any kind of treatment, the infected
hepatocytes produce HCV at a rate p, which has a clearance rate of c. The production of HCV is lowered
by a factor of (1− ǫp) upon the administration of IFN treatment, where ǫp is the efficacy of IFN. The model
excludes the role of IFN in blocking the infection, as it was observed to have minimal effect in this case
[1, 8]. This model admits two steady states [9], namely the uninfected state,
T (u) =
Tmax
2r
[
r − d+
√
(r − d)2 +
4rs
Tmax
]
, I(u) = 0, V (u) = 0,
and the infected state,
T (i) =
1
2
[
−D +
√
D2 +
4sTmax
rA2
]
, I(i) = T (i)(A− 1) + Tmax −B,V
(i) =
(1− ǫp)pI
(i)
c
,
where,
A =
(1− ǫp)pβTmax
cr
,B =
δTmax
r
,D =
1
A
[
Tmax +
dB
δA
−B
(
1
A
+ 1
)]
.
Under the physiological conditions r > d and s ≤ dTmax, it can be shown [9] that there is a transcritical
bifurcation at,
(1− ǫp) =
c(δTmax + rT
(u) − rTmax)
pβT (u)Tmax
= C∗1 (say).
In other words, the uninfected steady state is stable if (1− ǫp) < C∗1 , while the infected steady state is stable
if (1− ǫp) > C∗1 .
3 OPTIMAL CONTROL PROBLEM FOR MONOTREATMENT MODEL
In this section, we present an optimal control problem motivated by biomedical considerations. The goal
is to formulate the problem such that, the integral and terminal values of HCV (V ), as well as that of the
infected hepatocytes (I) are minimized with respect to the control (ǫp) (on the lines of [18]). The problem
also incorporates the necessity of minimizing the therapeutic side effects of IFN. Keeping these goals in
mind, the objective functional, to be minimized, is defined as,
J =
1
2
[
S22I(tf )
2 + S33V (tf )
2
]
+
1
2
∫ tf
ti
[
Q22I(t)
2 +Q33V (t)
2 +RǫP (t)
2
]
dt,
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where, Sii and Qii represent the cost coefficient associated with the respective variables. For the purpose of
notational convenience, we define the state variables as x1 = T, x2 = I, x3 = V and the control variable as
u = ǫp. The state equations in the new variables are given by,
x˙1 = s+ rx1
(
1−
x1 + x2
Tmax
)
− dx1 − βx1x3
x˙2 = βx1x3 + rx2
(
1−
x1 + x2
Tmax
)
− δx2
x˙3 = (1− u)px2 − cx3. (3.1)
By defining the state vector x =
(
x1 x2 x3
)⊤
, the above equations can be written as x˙ = f(x(t), u(t), t).
The initial condition, x(ti) = x0, is taken to be the infected steady state concentrations before the initiation
of the treatment (when ǫp = u = 0) [9].
The above problem can be viewed as a part of a more general setting as described below [18, 22]:
To find an admissible optimal control u∗ : [ti, tf ]→ [u,u], which for the system x˙(t) = f(x(t),u(t), t),x(ti) =
x0, minimizes the cost functional
J =
1
2
x
⊤(tf )Sx(tf ) +
∫ tf
ti
1
2
[
x
⊤(t)Qx(t) + u⊤(t)Ru(t)
]
= K (x(tf ), tf ) +
∫ tf
ti
L(x(t),u(t), t)dt.
The Hamiltonian, defined by using the dynamic constraint f(x(t),u(t), t) and the Lagrangian L(x(t),u(t), t)
through the adjoint vector λT (with the same dimension as the state vector), is as follows,
H(x(t),u(t), λ(t), t) = L(x(t),u(t), t) + λT (t)f(x(t),u(t), t).
Using Pontryagin’s minimum principle, the necessary conditions (in terms of the Hamiltonian) for u∗ to be
an optimal control are [18, 22],
(a) x˙∗(t) = ∇λH(x∗(t),u∗(t), λ∗(t), t) = f(x∗(t), u∗(t), t).
(b) x∗(ti) = x0.
(c) λ˙∗(t) = − [∇xH(x∗(t),u∗(t), λ∗(t), t)]⊤ = − [∇xL(x∗(t),u∗(t), t)]⊤−[∇xf(x∗(t),u∗(t), t)]⊤ λ(t).
(d) λ∗(tf ) = ∇xK (x∗(tf ), tf ) = Sx∗(tf ).
(e) ∇uH(x∗(t),u∗(t), λ∗(t), t) = ∇uL(x∗(t),u∗(t), t) + λ(t)⊤∇uf(x∗(t),u∗(t), t) = 0.
The optimal control system thus, comprises of a coupled forward state equation and a backward adjoint
equation, along with the regular control. This problem, being nonlinear and coupled in nature, needs to be
solved using concurrent and iterative numerical procedures. In this paper, the solution is approximated by
the steepest gradient method [18, 22].
1. Approximation starts with an initial guess for the control u(t) = u(0)(t).
2. Using this control u(0)(t), x(0)(t) is found by numerically solving x˙ = f(x(t),u(0)(t), t),x(ti) = x0,
which is then used to solve λ˙ = −∇xH(x(0)(t),u(0)(t), λ(t), t), λ(tf ) = Sx(0)(tf ) to obtain λ(0)(t).
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3. The gradient ∇uH(x(0)(t),u(0)(t), λ(0)(t), t) is evaluated to obtain the updated control as follows,
u
(1)(t) = u(0)(t)− τ(0)∇uH(x
(0)(t),u(0)(t), λ(0)(t), t)
The above iterative process for the k + 1-th iteration is given by,
u
(k+1)(t) = u(k)(t)− τ(k)∇uH(x
(k)(t),u(k)(t), λ(k)(t), t)
This procedure is repeated until some convergence criterion, such as ||u(k+1)(t)−u(k)(t)|| < tol or J (k)−
J (k+1) < tol, is satisfied (the latter was used in this paper). Runge-Kutta method of order 4 is used for
numerically integrating x and λ.
Parameter Value ([9]
s 1.0 cell ml−1 day−1
d 0.01 day−1
p 2.9 virions day−1
β 2.25 × 10−7 ml day−1 virions−1
c 6.0 day−1
δ 1.0 day−1
r 2.0 day−1
Tmax 3.6 × 10
7 cells ml−1
Table 1: Parameter values for the optimal control simulation
4 RESULTS AND DISCUSSION FOR MONOTREATMENT MODEL
We implemented the above procedure using MATLAB TM. The optimal control is approximated using
the steepest gradient method for the parameter values given in Table 1 [9]. The efficacy ǫp can theoretically
lie between 0 and 1. Accordingly, u is set to be 0, which corresponds to zero effectiveness of the drug. The
value of u, however, is taken to be less than 1, for biomedical observations suggest that a perfect efficacy is
unlikely to be achieved. A more mathematical justification can be presented using pharmacokinetic models
(such as Powers et al. [23]), where the term for efficacy cannot become 1 for all possible values of drug
doses.
The optimal control (u∗) is simulated over a period of 50 days and is presented in Figure 1. The cost
coefficients used were S22 = S33 = 10−5, Q22 = Q33 = 10−5 and R = 0.1. It can be observed from the
figure that, the optimal IFN efficacy remains at u = 0.98 for about three weeks and gradually decreases to
about 0.7 over the next 4 weeks. The same simulation, run over a period of ten weeks, exhibits a slower
rate of decline in the optimal efficacy. However, the time window for which the optimal efficacy remains
at u, is roughly unchanged. The simulations are repeated for various values of matrices S, Q and R, for
various treatment time windows. The results indicate that in responsive patients, the length of this period
of administering high dosage does not vary by much as long as the cost coefficient R is relatively small.
Higher values of R result (as one expects) in a shorter period of high dosage. This is of crucial importance
when deciding on an optimal therapy of drugs with minor side-effects.
The dynamics of the uninfected (T ) and infected (I) hepatocyte concentrations and HCV (V ) levels
under the application of optimal efficacy (Figure 1) are given in Figure 2. The viral load shows a triphasic
decline, which is in line with the biomedical observations [9]. The optimal treatment exhibits a rapid first
phase decline in the viral load during the first couple of days, followed by a stable concentration over the
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next couple of weeks and finally a faster decline for the rest of the treatment period. These observations
are consistent with the results in [7, 8, 9]. The infected hepatocyte concentration decreases rapidly from the
third week of the treatment, whereas, the uninfected hepatocyte concentration increases over the course of
the first three weeks of therapy and remains close to Tmax (maximum liver volume) for the rest of the period.
Interestingly, the level of optimal efficacy remains at u until a point (three weeks in this case) where the
viral load and the infected hepatocyte count starts showing a rapid decline, accompanied by the uninfected
hepatocyte level approaching the maximum liver volume. This is in line with the notion of administering
high dosage early in the treatment [18] and that the dosage should decrease once the results are visible.
Usually the detection level of virions for HCV patients is taken to be of the order ∼ 102 HCV RNA copies
per ml [1]. We define td to be the time at which the virion levels become undetectable. As seen in Figure 2,
the viral load drops below this level for u∗ after about 6 weeks (i.e, td = 6 weeks). We then examine the state
dynamics of a large number of sets of sample parameter values under this optimal control u∗. The sample
parameter values are generated using the Latin Hypercube Sampling technique. We implement this sampling
method to generate a large number of sample points for all parameter values from a multivariate distribution
(normal, in our case, with a specified mean vector →µ and covariance matrix Σ) [24]. For the theoretical and
computational aspects of this method, the interested reader may refer to the book by Glasserman [25]. We
take the mean vector
→
µ to be the values specified in Table 1, i.e., µ = (s, d, p, β, c, δ, r, Tmax). The diagonal
covariance matrix Σ is taken as diag
(
s2, d2, p2, β2, c2, δ2, r2, T 2max
) [24]. Once the sets of parameter values
are generated they are tested for positivity and physiological conditions (r > d and s ≤ dTmax [9]) till
exactly 500 such sets are accepted. The sample sets, which failed this test, are rejected. We, then, examine
the dynamics of the state variables (by numerically approximating Equation (3.1)) for all the accepted sample
parameter sets under the application of the optimal therapy u∗. We keep track of the time (td) required for
the viral load to fall below detection level of 102 for each sample set. The cumulative distribution of td
is shown in Figure 3. The figure shows that, about half of the cases exhibit a short-term response to the
optimal therapy, which obviously includes the acute cases, where the virus clears out irrespective of whether
any treatment is administered or not [24].
We also perform Spearman’s test to check for monotonic relations between each of the sample parameters
sets and the time required (td) for the viral load to drop below detection level. This test indicates a strong
negative correlation between td and the death rate of infected hepatocytes δ. A reason for this could be the
strong negative correlation between δ and the transcritical bifurcation (C∗1 ) over the same distribution [24].
Biologically, the cases, which present with a higher death rate of infected hepatocytes, are more likely (as
compared to other parameters) to respond to therapy. Also, td shows a mild monotonic correlation with r. A
higher rate of proliferation results in higher infected hepatocyte levels, which in turn supports the production
of virions. Therefore, the cases which present with a high rate of proliferation might not achieve short-term
response.
5 MODEL FOR COMBINATION TREATMENT WITH IFN AND RIBAVIRIN
In this section, we present an extended model which includes the therapeutic effects of ribavirin to the
model discussed in Section 2. This model, for combination treatment with IFN and ribavirin, comprises of
four coupled ODEs:
dT
dt
= s+ rT
(
1−
T + I
Tmax
)
− dT − βTVI
dI
dt
= βTVI + rI
(
1−
T + I
Tmax
)
− δI
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dVI
dt
= (1− ρ)(1− ǫp)pI − cVI
dVNI
dt
= ρ(1− ǫp)pI − cVNI . (5.1)
Ribavirin works by rendering a fraction of the newly produced virions non-infectious. The virion population
is divided into two different virion populations, namely infectious (VI ) and non-infectious (VNI ), as a result
of administration of ribavirin with an efficacy of ρ. This model also admits two steady states [9], namely the
uninfected state,
T (u) =
Tmax
2r
[
r − d+
√
(r − d)2 +
4rs
Tmax
]
, I(u) = 0, V
(u)
I = 0, V
(u)
NI = 0.
and the infected state,
T (i) =
1
2
[
−D +
√
D2 +
4sTmax
rA2
]
, I(i) = T (i)(A− 1) + Tmax −B
V
(i)
I =
(1− ǫp)(1 − ρ)pI
(i)
c
, V
(i)
NI =
ρV
(i)
I
(1− ρ)
,
where,
A =
(1− ǫp)(1 − ρ)pβTmax
cr
,B =
δTmax
r
,D =
1
A
[
Tmax +
dB
δA
−B
(
1
A
+ 1
)]
.
Under the physiological conditions r > d and s ≤ dTmax, it can be shown [9] that there is a transcritical
bifurcation at,
(1− ǫp)(1 − ρ) =
c(δTmax + rT
(u) − rTmax)
pβT (u)Tmax
= C∗2 (say).
In other words, the uninfected steady state is stable if (1 − ǫp)(1− ρ) < C∗2 while the infected steady state
is stable if (1− ǫp)(1− ρ) > C∗2 .
5.1 OPTIMAL CONTROL PROBLEM FOR COMBINATION TREATMENT WITH IFN AND RIBAVIRIN
We define a slightly modified objective functional for the four equation model outlined in the previous
section. In defining the objective functional, we consider the integral values of the infected hepatocyte
concentration (I) and infectious viral load (VI ), as well as the terminal values of infected hepatocytes and
both the virion populations (VI and VNI ). The integral value of the non-infectious viral load is not taken into
account (i.e., has zero cost coefficient), since it does not contribute towards the infectivity of hepatocytes
during the course of the treatment. Also, the functional incorporates the need to minimize the therapeutic
side-effects of both IFN and ribavirin. Under these biomedical considerations, the objective functional for
combination therapy is defined as,
J =
1
2
[
S22I(tf )
2 + S33VI(tf )
2 + S44VNI(tf )
2
]
+
1
2
∫ tf
ti
[
Q22I(t)
2 +Q33VI(t)
2 +R11ǫp(t)
2 +R22ρ(t)
2
]
dt,
The state vector for this model is defined as x =
(
x1 x2 x3 x4
)⊤
, where x1 = T, x2 = I, x3 = VI and
x4 = VNI . Similarly, the control vector is defined as u =
(
u1 u2
)⊤
, where u1 = ǫp and u2 = ρ. The
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system described in Equation (5.1) is written as x˙ = f(x(t),u(t), t) with the initial condition x(ti) = x0,
which, as in case of the first model, is taken to be the pre-treatment (u1 = u2 = 0) infected steady state
concentrations. The subsequent mathematical and numerical treatment of the problem is analogous to the
approach adopted for the monotreatment model.
5.2 RESULTS AND DISCUSSIONS FOR COMBINATION TREATMENT WITH IFN AND RIBAVIRIN
As in the case of monotreatment, the parameter values are taken from Table 1. The optimal control
problem is solved using the steepest gradient method described in Section 2. The cost coefficients used for
numerical implementation are S22 = S33 = S44 = 10−5, Q22 = Q33 = 10−5 and R11 = R22 = 0.1.
The optimal combination therapy u∗ and the dynamics of the state variables under u∗ are presented
in Figure (4) and (5) respectively. As it can be seen from the figures, the patient response, as a result of
combination therapy, is better as compared to monotreatment regimen.
It is observed from Figure (5) that, the viral load drops below the detection level (102) after about 30 days
of combination treatment as compared to 40 days in case of monotreatment. In addition, decline in infected
hepatocyte levels in this case is steeper, in comparison with the decline under monotherapy. The optimal
control remains at u = (0.98, 0.98)⊤ for about three weeks and then gradually decreases over the rest of
the period, as it was seen in case of monotherapy as well. If the treatment window is varied, length of this
period of high efficacy remains roughly unchanged for smaller values of R, which reiterates the point made
earlier that, in case of drugs with minor side effects, the duration of high dosage remains approximately the
same. As was the case with monotherapy, the infectious viral load (VI ) shows a triphasic decline during
the period of administering high dosage, while the uninfected hepatocytes (T ) exhibit an increase in levels.
Beyond this period, the uninfected hepatocyte count remains close to Tmax. The infected hepatocyte count
(I) shows a concurrent constant level followed by a decline. This observation is consistent with the idea
that, high doses are administered until visible physical progress is achieved, after which, dosage is reduced.
We use the Latin hypercube sampling technique described in Section 3 to generate sample parameters,
using the same
→
µ and Σ as before along with positivity and physiological restrictions [9] for this model
as conditions for acceptability. The cumulative distribution for td is determined for the accepted sample
parameter sets and is shown in Figure (6). The graph for this distribution shows an improvement in patient
response (60% after 50 days) under combination therapy, as compared to monotreatment success rate of
about 50%. Spearman’s tests, between sample parameters and td, show that a strong negative correlation ex-
ists between δ and td. This is consistent with our earlier work [24], where δ was found to be the most crucial
parameter in determining the patient response. Also, a moderate positive correlation was observed between
the rate of proliferation r and td. A higher proliferation of infected hepatocytes supports the replication of
HCV, a result also noted in [24].
6 CONCLUSION
In this paper, we consider two well established models for HCV dynamics, incorporating the efficacy
of the drugs administered. The effects of the drugs as manifested by this model, vary greatly amongst
individual patents, depending upon the parameter variation. A transcritical bifurcation condition which
identifies the stability criterion for the uninfected and infected steady state is presented. Optimal treatment
protocol is determined for both the models, one for monotreatment with IFN and the other for a combination
therapy of IFN and ribavirin. The optimal therapy shows an initial high level followed by a decline once
the hepatocyte gradually gets restored. The results, obtained in this paper, are consistent with biomedical
observations relating therapeutic protocols, especially, the notion of administering high dosage in the early
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stages of infection and gradual lowering of the dosage after the patient has shown signs of recovery.
With the goal of examining the consequences of administering the optimal efficacy of the two drugs
in case of several patient scenarios, we generate a large set of patient parameters using Latin hypercube
sampling. The state dynamics for the generated parameter sets are studied under the optimal therapy. The
results indicated a better response in case of combination therapy as compared to monotherapy. Statistical
tests, presented in this paper, show that, patient recovery is highly influenced by the death rate of infected
hepatocytes. Also a higher proliferation rate abets the viral replication.
Such statistical analysis can be helpful in determining the optimal therapy on an individual basis, by
recognizing the major factors which influence patient response. We believe that the analysis presented in
this paper, combined with pharmacokinetics studies, could play an important role in developing improved
HCV treatment regimen.
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Figure 1: Optimal Control for Monotherapy
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Figure 3: Distribution of td for Monotherapy
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Figure 4: Optimal Control for Combination Therapy
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Figure 5: State Dynamics for Combination Therapy
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Figure 6: Distribution of td for Combination Therapy
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